50+ interactive charts, automated change detection, and agent-ready data export — everything your team needs to stay ahead.
Analyzing a portfolio of hundreds of clinical trials requires exporting data, building pivot tables, and creating charts manually — a process that takes hours and produces static snapshots.
ClinicaLister's interactive dashboard provides 50+ clickable charts that update in real time. Every chart element acts as a cross-filter — click a bar, slice, or segment to instantly refine the entire dashboard.
Breakdown by clinical phase (Phase I through Phase IV, Early Phase)
Recruitment and execution status (Recruiting, Active, Completed, Terminated, Withdrawn)
Interventional vs. observational vs. expanded access classification
Target population segmentation (Child, Adult, Older Adult)
Most prevalent conditions and diseases across the portfolio
Deduplicated distribution of MONDO-linked diseases across the portfolio — every synonym collapsed into its canonical term
When trials were most recently modified, with configurable date field
Phase × sponsor cross-tab showing competitor positioning across development stages
Historical modification activity patterns by sponsor over time
Distribution of EU Clinical Trials (CTIS) cross-references by status and member state
Global spread of trial sites by country
Continental and sub-regional aggregation
Top clinical trial sites and research centers
Sponsor organization frequency and portfolio concentration
FDA vs. EMA regulatory source breakdown
Most common medications, distinguishing verified from AI-suggested
Formulation types with automatic splitting of compound forms
European authorization status distribution
Drug classification by EMA therapeutic categories
FDA device class (I, II, III) with implant and life-sustaining flags
Most common medical devices across trials
FDA device submission pathway breakdown (510(k), PMA, HDE, DE NOVO)
FDA advisory committee assignment distribution
Device categorization by medical specialty
Orphan drug, fast track, breakthrough therapy, and accelerated approval designations
Severity distribution of FDA Adverse Event Reporting System data for linked drugs
Active shortage tracking with supply chain impact assessment
National Average Drug Acquisition Cost trends for linked pharmaceutical products
Urgency-classified timeline of marketing exclusivity expirations
Patent expiration dates with competitive landscape impact analysis
Proportional Reporting Ratio and Reporting Odds Ratio for pharmacovigilance signals
Medical device adverse event categorization from FDA MAUDE reports
FDA boxed warning status distribution across linked drug products
Drug classification by mechanism of action and pharmacological effect
Drug-trial relationship context showing role of drug in trial (intervention, comparator, concomitant)
Device-trial relationship context and device role classification
Distribution of verified vs. AI-suggested drug links with community validation progress
Distribution of verified vs. AI-suggested device links with validation metrics
MAUDE-based safety signal analysis for medical devices linked to trials
Bubble chart correlating patent expiry year with Medicare Part D spending — identify high-value drugs approaching generic entry
Comparative authorization timelines between FDA and EMA — visualize regulatory divergence across drug approvals
Competitive drug pairings showing head-to-head comparator relationships across trials
Sponsor density per molecule — identify crowded therapeutic targets and white-space opportunities
Polypharmacy analysis showing co-administered drugs across trial protocols
Breakthrough, orphan, fast track, and accelerated approval designation dynamics over time
Every chart element is clickable. Select any segment to instantly filter all other charts, tables, and views. This enables rapid exploratory analysis — drill down from a portfolio-level overview to a specific subset of trials in seconds.
A dedicated "Rare diseases only" toggle in the dashboard header instantly narrows the entire portfolio to trials linked to a MONDO disease flagged by Orphanet. Every chart, table, map marker, and monitoring alert reflects the rare-disease subset — a single-click competitive differentiator for Regulatory Affairs, Medical Affairs, and orphan-drug program leads.
When a clinical trial changes its status, modifies its protocol, or updates enrollment numbers, your team may not discover it for days or weeks — potentially missing competitive signals or regulatory triggers.
ClinicaLister monitors your followed trials throughout the day and captures every change as a field-level event — classified by severity — so the change itself becomes the unit of intelligence, not the raw record. Your team focuses on what actually moved.
These are the defaults — severity is fully configurable. Assign each monitored field its own level (Critical, High, Medium, or Low) so alerts match exactly how your team triages change.
Status changes to Terminated, Withdrawn, or Suspended
Phase changes, primary endpoint modifications, new safety signals
Enrollment updates, site additions or removals, timeline changes
Administrative updates, contact changes, minor text edits
At-a-glance metrics showing the count of Critical, High, Medium, and Low severity alerts across your portfolio
Visual timeline of all detected modifications, filterable by severity, trial, sponsor, and date range
See exactly what changed — formatted field values showing previous and current states side by side
Cross-sponsor analysis revealing modification patterns and activity levels
Track which trials and data fields are modified most frequently — surfacing instability or rapid development activity
Define what constitutes each severity level for your organization
An integrated AI assistant provides contextual interpretation of detected changes — explaining why modifications may have occurred, their potential impact on the trial, and recommended follow-up actions.
Export your entire regulatory intelligence portfolio — trials, drugs, devices, patents, safety data — in a single structured XLSX file with 22 cross-linked sheets. An embedded AI prompt provides context for automated analysis, and smart chunking handles portfolios of any size.